Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer

M. J. Klomp, S. U. Dalm, M. de Jong, R. A. Feelders, J. Hofland, L. J. Hofland*

*Corresponding author for this work

Research output: Contribution to journalReview articlePopular

8 Citations (Scopus)

Abstract

Both somatostatin (SST) and somatostatin receptors (SSTRs) are proteins with important functions in both physiological tissue and in tumors, particularly in neuroendocrine tumors (NETs). NETs are frequently characterized by high SSTRs expression levels. SST analogues (SSAs) that bind and activate SSTR have anti-proliferative and anti-secretory activity, thereby reducing both the growth as well as the hormonal symptoms of NETs. Moreover, the high expression levels of SSTR type-2 (SSTR2) in NETs is a powerful target for therapy with radiolabeled SSAs. Due to the important role of both SST and SSTRs, it is of great importance to elucidate the mechanisms involved in regulating their expression in NETs, as well as in other types of tumors. The field of epigenetics recently gained interest in NET research, highlighting the importance of this process in regulating the expression of gene and protein expression. In this review we will discuss the role of the epigenetic machinery in controlling the expression of both SSTRs and the neuropeptide SST. Particular attention will be given to the epigenetic regulation of these proteins in NETs, whereas the involvement of the epigenetic machinery in other types of cancer will be discussed as well. In addition, we will discuss the possibility to target enzymes involved in the epigenetic machinery to modify the expression of the SST-system, thereby possibly improving therapeutic options.

Original languageEnglish
Pages (from-to)495-510
Number of pages16
JournalReviews in Endocrine and Metabolic Disorders
Volume22
Issue number3
DOIs
Publication statusPublished - 21 Oct 2020

Bibliographical note

Funding Information:
L.J. Hofland: research grants from Novartis, Ipsen and Strongbridge; J. Hofland: speaker and travel fee from Ipsen, advisory board Novartis; R.A. Feelders: speaker fee Ipsen; no disclosures for S.U. Dalm, M. de Jong and M.J. Klomp.

Funding Information:
We thank the Medical Library of the Erasmus MC for assisting with the literature search. L.J. Hofland: research grants from Novartis, Ipsen and Strongbridge; J. Hofland: speaker and travel fee from Ipsen, advisory board Novartis; R.A. Feelders: speaker fee Ipsen; no disclosures for S.U. Dalm, M. de Jong and M.J. Klomp.

Publisher Copyright:
© 2020, The Author(s).

Fingerprint

Dive into the research topics of 'Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer'. Together they form a unique fingerprint.

Cite this